ImmuPharma (LON:IMM) Shares Down 5.3% – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s share price traded down 5.3% on Wednesday . The company traded as low as GBX 5.04 ($0.06) and last traded at GBX 5.59 ($0.07). 46,394,512 shares were traded during mid-day trading, an increase of 88% from the average session volume of 24,729,924 shares. The stock had previously closed at GBX 5.90 ($0.07).

ImmuPharma Trading Down 20.0 %

The firm’s 50-day moving average price is GBX 1.92 and its 200-day moving average price is GBX 1.78. The stock has a market capitalization of £19.66 million, a PE ratio of -472.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.